Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$544.83 USD

544.83
98,264

+1.17 (0.22%)

Updated Jun 10, 2024 04:00 PM ET

After-Market: $544.84 +0.01 (0.00%) 7:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 248)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Allscripts' (MDRX) Q3 Earnings Beat Estimates, Margins Up

Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.

Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down

Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.

BD (BDX) Beats on Q4 Earnings and Revenues, FY22 View Issued

Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal fourth quarter, driving up the overall top line.

Avanos Medical (AVNS) Q3 Earnings Lag Estimates, Revenues Top

Avanos Medical's (AVNS) third-quarter 2021 results gains from strength in the Pain Management segment.

PacBio's (PACB) Q3 Earnings Miss Estimates, Revenues Top

PacBio (PACB) sees strength in Q3 product revenues, led by robust consumable and instrument sales.

Chemed (CHE) Q3 Earnings Beat Estimates, Full-Year EPS View Up

Chemed (CHE) reports better-than-expected earnings and revenues in the third-quarter 2021, with a solid performance by the Roto-Rooter segment driving the top line.

Chemed (CHE) Q3 Earnings and Revenues Top Estimates

Chemed (CHE) delivered earnings and revenue surprises of 13.45% and 1.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Chemed (CHE) Q3 Earnings Expected to Decline

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Chemed (CHE) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Chemed (CHE) Moves to Buy: Rationale Behind the Upgrade

Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Chemed (CHE) Up 1.9% Since Last Earnings Report: Can It Continue?

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Chemed (CHE) Upgraded to Buy: Here's Why

Chemed (CHE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks.com featured highlights include: Cathay General Bancorp, Bio-Rad Laboratories, Chemed Corp, Materialise and Arbor Realty Trust

Zacks.com featured highlights include: Cathay General Bancorp, Bio-Rad Laboratories, Chemed Corp, Materialise and Arbor Realty Trust

Shrabana Mukherjee headshot

5 Stocks to Buy as Analysts Initiate Coverage

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like CATY, BIO, CHE, MTLS and ABR.

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

Investors are optimistic about Chemed (CHE) on strong segmental growth and raised Roto-Rooter and earnings guidance for 2021.

DaVita (DVA) Beats on Q2 Earnings, Raises 2021 EPS View

DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.

PacBio's (PACB) Q2 Earnings Miss Estimates, Revenues Top

PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.

CVS Health (CVS) Q2 Earnings Beat Estimates, EPS View Up

CVS Health (CVS) Q2 adjusted EPS drops year over year on escalating costs and expenses which are putting pressure on margins.

Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top

Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.

Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up

Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.

AmerisourceBergen (ABC) Q3 Earnings and Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.

Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.

Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Expand

Zimmer Biomet (ZBH) sales improve across all its operating segments and geographies on recovery from the pandemic in the months of the second quarter.

Henry Schein (HSIC) Q2 Earnings Top Estimates, 2021 EPS View Up

Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the second quarter.

Bruker (BRKR) Q2 Earnings Beat Estimates, 2021 Guidance Up

Bruker (BRKR) reports better-than-expected revenues for the second quarter of 2021 on strong segmental performance driving the top line.